Table 3.

Clinical outcomes

Clinical outcomes	Values
Treatment success, n, %	27 (90)
Surgical referral, n, %	0 (0)
Survival upon hospital discharge, n, %
Mortality at 30 days, n, %	30 (100)
	3 (10)
Median length of hospital stay, days (IQR)	17 (11.7–24.2)
Median length of stay from first dose intrapleural therapy, days (IQR)
Median duration of intercostal catheter in pleural cavity, days (IQR)	8 (4.8–12)
Median duration of intercostal catheter in pleural cavity post first dose intrapleural therapy, days (IQR)
Patients who received ≤ 2 doses intrapleural therapy, n (%)	10 (8–14.3)
	6 (4–7.3)
	8 (26.7)
Adverse eventsa, n, %
Chest pain requiring escalation of analgesics	6 (20)
Gastrointestinal bleed	1 (3.3)
Clinical deterioration	1 (3.3)
Hemoptysis	1 (3.3)

IQR interquartile range, SD standard deviation, CRP C-reactive protein, WBC white cell count

^aSame patient might experienced more than one adverse events